Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma | NeoGenomics Laboratories

Publication date

Mon, 06/06/2022 - 12:00

Year

Subtitle

ASCO 2022

File

Leveraging_personalized_circulating_DNA_%28ctDNA%29_for_detection_and_monitoring_of_molecular_residual_disease_in_high-risk_melanoma.pdf (582.29 KB)

Division